Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline

Jack, C. R. Jr et al. A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology 87, 539–547 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jack, C. R. Jr et al. NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Dubois, B. et al. Clinical diagnosis of Alzheimer’s disease: recommendations of the International Working Group. Lancet Neurol. 20, 484–496 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brookmeyer, R. & Abdalla, N. Estimation of lifetime risks of Alzheimer’s disease dementia using biomarkers for preclinical disease. Alzheimers Dement. 14, 981–988 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Dubois, B. et al. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer’s disease (INSIGHT-preAD): a longitudinal observational study. Lancet Neurol. 17, 335–346 (2018).

Article  CAS  PubMed  Google Scholar 

Donohue, M. C. et al. Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons. JAMA 317, 2305–2316 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jack, C. R. Jr et al. Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk. Brain Commun. 4, fcac017 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Nelson, P. T. et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362–381 (2012).

Article  PubMed  Google Scholar 

Ossenkoppele, R. et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 139, 1551–1567 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Ossenkoppele, R. et al. Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease. Neurology 92, e601–e612 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jack, C. R. Jr et al. Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia. JAMA 321, 2316–2325 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ossenkoppele, R., van der Kant, R. & Hansson, O. Tau biomarkers in Alzheimer’s disease: towards implementation in clinical practice and trials. Lancet Neurol. 21, 726–734 (2022).

Article  CAS  PubMed  Google Scholar 

Leuzy, A. et al. 2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2121–2139 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fleisher, A. S. et al. Positron emission tomography imaging with [18F]flortaucipir and postmortem assessment of Alzheimer disease neuropathologic changes. JAMA Neurol. 77, 829–839 (2020).

Article  PubMed  Google Scholar 

Moloney, C. M., Lowe, V. J. & Murray, M. E. Visualization of neurofibrillary tangle maturity in Alzheimer’s disease: a clinicopathologic perspective for biomarker research. Alzheimers Dement. 17, 1554–1574 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leuzy, A. et al. Diagnostic performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 77, 955–965 (2020).

Article  PubMed  Google Scholar 

Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Young, C. B. et al. Divergent cortical tau positron emission tomography patterns among patients with preclinical Alzheimer disease. JAMA Neurol. 79, 592–603 (2022).

Article  PubMed  Google Scholar 

Johnson, K. A. et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann. Neurol. 79, 110–119 (2016).

Article  PubMed  Google Scholar 

Schöll, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971–982 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Gordon, B. A. et al. Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers. Brain 142, 1063–1076 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Pontecorvo, M. J. et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain 140, 748–763 (2017).

PubMed  PubMed Central  Google Scholar 

Ossenkoppele, R. et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. JAMA Neurol. 78, 961–971 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Sperling, R. A. et al. The impact of amyloid-beta and tau on prospective cognitive decline in older individuals. Ann. Neurol. 85, 181–193 (2019).

CAS  PubMed  PubMed Central  Google Scholar 

Hanseeuw, B. J. et al. Association of amyloid and tau with cognition in preclinical Alzheimer disease: a longitudinal study. JAMA Neurol. 76, 915–924 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Chen, S. D. et al. Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study. Transl. Psychiatry 11, 483 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bucci, M., Chiotis, K. & Nordberg, A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol. Psychiatry 26, 5888–5898 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Teng, E. et al. Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer’s disease. Alzheimers Res. Ther. 13, 196 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Biel, D. et al. Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res. Ther. 13, 137 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pontecorvo, M. J. et al. A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia. Brain 142, 1723–1735 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Cho, H. et al. Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J. Nucl. Med. 60, 1611–1621 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strikwerda-Brown, C. et al. Association of elevated amyloid and tau positron emission tomography signal with near-term development of Alzheimer disease symptoms in older adults without cognitive impairment. JAMA Neurology 79, 975–985 (2022).

Wolters, E. E. et al. Clinical validity of increased cortical uptake of [18F]flortaucipir on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase biomarker development framework. Eur. J. Nucl. Med. Mol. Imaging 48, 2097–2109 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papp, K. V., Rentz, D. M., Orlovsky, I., Sperling, R. A. & Mormino, E. C. Optimizing the preclinical Alzheimer’s cognitive composite with semantic processing: the PACC5. Alzheimers Dement. (N Y) 3, 668–677 (2017).

Article  Google Scholar 

Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818–2830 (2020).

Article  PubMed  Google Scholar 

Insel, P. S. et al. Determining clinically meaningful decline in preclinical Alzheimer disease. Neurology 93, e322–e333 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Dumitrescu, L. et al. Genetic variants and functional pathways associated with resilience to Alzheimer’s disease. Brain 143, 2561–2575 (2020).

Article  PubMed  PubMed Central 

留言 (0)

沒有登入
gif